Gabrielle Masson

Industry analyst Gabrielle Masson and expert Max Bayer discuss the surge in biopharma layoffs in Q1 2024, analyzing the reasons behind this trend. They also highlight positive industry developments amidst the challenges faced by companies. The podcast explores investment dynamics, job market realities, and the shift towards cautious expansion in the biopharma sector.

Annalee Armstrong, a key figure in Fierce Biotech's annual reports, and Gabrielle Masson, a presenter for the Fierce 15 at NYSE, delve into the fascinating selection process for this year's Fierce 15. They reveal the unique qualities that set these innovative biotech companies apart, from groundbreaking RNA therapies inspired by nature to the rise of women-led firms. The duo also shares insights into collaborations tackling obesity and mental health, showcasing the vibrant landscape of biotech's future.

Fierce Biotech and Fierce Pharma reporters Gabrielle Masson and Angus Liu discuss ASCO's biggest data drops and trends. They share insights on Keytruda's competition, Merck's strategic shift, and novel cancer vaccines. Experience the ASCO exhibit hall adventures with virtual reality and unique booth encounters. Learn about the intense competition, challenges, and amusing moments at the international conference.

Fierce Biotech members Annalee Armstrong and Gabrielle Masson discuss the challenges and advancements in cell therapy, including a notable shift towards autoimmune treatments, manufacturing constraints, and the potential impact of CAR-T therapy in various medical fields.

This podcast looks back at the year in biotech, focusing on massive industry layoffs and favorite stories, including a Taylor Swift appearance. Topics also include IPO trends, Alzheimer's meds, and the impact on the Down syndrome community.